Magazine Article | January 2, 2019

Is China's Golden Era Ending?

Source: Life Science Leader

By Gail Dutton, Contributing Writer
Follow Me On Twitter @GailLdutton

“This is the golden era of healthcare in China,” according to Greg Scott, CEO and founder of ChinaBio. That may have been true as recently as late summer, but the trade war that began around August 2018 has seen the value of Chinese life sciences companies fall about 30 percent. By November, even senior leaders seemed to be backing down.


The “Made in China 2025” plan that was announced in 2015 eventually will put the brakes on foreign investment. As the South China Morning Post pointed out at the end of October, “The Made in China 2025 strategy aims to guide the country’s industrial modernization, including the substitution of foreign technology with innovation developed on the mainland.”